Effect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus - PubMed (original) (raw)

Clinical Trial

Effect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus

S Kado et al. Diabetes Res Clin Pract. 1998 Jul.

Abstract

The effect of acarbose, an alpha-glucosidase inhibitor, on postprandial glucose and lipid metabolism was investigated in patients with type 2 diabetes mellitus. Twenty patients (10 men and 10 women) with type 2 diabetes mellitus were studied. A test meal was taken with or without 100 mg of acarbose. The levels of plasma glucose, and serum immunoreactive insulin, lipids, apolipoproteins, and remnant-like particle cholesterol were investigated. Acarbose inhibited the postprandial increase of both plasma glucose and serum immunoreactive insulin. Acarbose also significantly suppressed the increase of serum triglycerides at 60, 90, and 120 min (P < 0.05 to P < 0.01), and the increase of serum remnant-like particle cholesterol at 60 and 120 min (P < 0.05). Acarbose inhibited the postprandial decline of apolipoprotein C-II, and decreased the postprandial serum apolipoprotein C-III level. These results suggest that acarbose may improve postprandial hyperlipidemia as well as postprandial hyperglycemia in patients with type 2 diabetes mellitus.

PubMed Disclaimer

Similar articles

• [Continuous blood glucose monitoring: the acute effect of acarbose on blood glucose variations].
  Herrmann BL, Schatz H, Pfeiffer A. Herrmann BL, et al. Med Klin (Munich). 1998 Nov 15;93(11):651-5. doi: 10.1007/BF03044876. Med Klin (Munich). 1998. PMID: 9872041 German.
• Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus.
  Schwartz EA, Koska J, Mullin MP, Syoufi I, Schwenke DC, Reaven PD. Schwartz EA, et al. Atherosclerosis. 2010 Sep;212(1):217-22. doi: 10.1016/j.atherosclerosis.2010.05.028. Epub 2010 May 25. Atherosclerosis. 2010. PMID: 20557887 Clinical Trial.
• Postprandial serum lipids and tissue lipoprotein lipase are acutely altered in rats by the alpha-glucosidase inhibitor acarbose.
  Picard F, Deshaies Y. Picard F, et al. Horm Metab Res. 1996 Aug;28(8):377-80. doi: 10.1055/s-2007-979819. Horm Metab Res. 1996. PMID: 8886823
• Acarbose: a review of US clinical experience.
  Coniff R, Krol A. Coniff R, et al. Clin Ther. 1997 Jan-Feb;19(1):16-26; discussion 2-3. doi: 10.1016/s0149-2918(97)80069-0. Clin Ther. 1997. PMID: 9083705 Review.
• The importance of hyperglycemia in the nonfasting state to the development of cardiovascular disease.
  Haffner SM. Haffner SM. Endocr Rev. 1998 Oct;19(5):583-92. doi: 10.1210/edrv.19.5.0343. Endocr Rev. 1998. PMID: 9793758 Review. No abstract available.

Cited by

• Critical evaluation of the role of acarbose in the treatment of diabetes: patient considerations.
  Rosak C, Mertes G. Rosak C, et al. Diabetes Metab Syndr Obes. 2012;5:357-67. doi: 10.2147/DMSO.S28340. Epub 2012 Oct 12. Diabetes Metab Syndr Obes. 2012. PMID: 23093911 Free PMC article.
• Suppression of the postprandial hyperglycemia in patients with type 2 diabetes by a raw medicinal herb powder is weakened when consumed in ordinary hard gelatin capsules: A randomized crossover clinical trial.
  Moreira FD, Reis CEG, Gallassi AD, Moreira DC, Welker AF. Moreira FD, et al. PLoS One. 2024 Oct 9;19(10):e0311501. doi: 10.1371/journal.pone.0311501. eCollection 2024. PLoS One. 2024. PMID: 39383145 Free PMC article. Clinical Trial.
• Is there a role for alpha-glucosidase inhibitors in the prevention of type 2 diabetes mellitus?
  Scheen AJ. Scheen AJ. Drugs. 2003;63(10):933-51. doi: 10.2165/00003495-200363100-00002. Drugs. 2003. PMID: 12699398 Review.
• Acute Flaxseed Intake Reduces Postprandial Glycemia in Subjects with Type 2 Diabetes: A Randomized Crossover Clinical Trial.
  Moreira FD, Reis CEG, Welker AF, Gallassi AD. Moreira FD, et al. Nutrients. 2022 Sep 10;14(18):3736. doi: 10.3390/nu14183736. Nutrients. 2022. PMID: 36145115 Free PMC article. Clinical Trial.
• Postprandial Hyperlipidemia: Its Pathophysiology, Diagnosis, Atherogenesis, and Treatments.
  Yanai H, Adachi H, Hakoshima M, Katsuyama H. Yanai H, et al. Int J Mol Sci. 2023 Sep 11;24(18):13942. doi: 10.3390/ijms241813942. Int J Mol Sci. 2023. PMID: 37762244 Free PMC article. Review.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Elsevier Science

• Other Literature Sources

  • The Lens - Patent Citations Database

• Medical

  • MedlinePlus Health Information